Overview

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Status:
RECRUITING
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Phase:
PHASE3
Details
Lead Sponsor:
Neurocrine Biosciences